Sonoma Pharmaceuticals provides updated investor presentation; no material changes disclosed

Sonoma Pharmaceuticals, Inc.

Exhibit 99.1 contains an updated corporate presentation dated October 2023.
Presentation reiterates focus on stabilized hypochlorous acid products across multiple therapeutic areas.
Company states products sold directly or via partners in 55 countries.
No new financial guidance, product approvals, or strategic transactions disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.